People · Operator
Named in public records as an officer, director or promoter · active 2011–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aerie Pharmaceuticals Inc | — | Biotechnology | Series D+ | $189.6M | $5.2B | 2012 |
| Tocagen Inc | — | Pharmaceuticals | Series C | $119.5M | $301.3M | 2023 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2011 |
DAVID GRYSKA at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DAVID GRYSKA on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Healy | 1 | 8 |
| Brian Levy | 1 | 8 |
| James I. Healy | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| David Epstein | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Bijan Salehizadeh | 1 | 5 |
| Jake Nunn | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| James Mazzo | 1 | 4 |
| Lota S Zoth | 1 | 4 |
| Franklin M. Berger | 1 | 4 |
| Donald Santel | 1 | 4 |
| Donald Williams | 1 | 4 |
| Gerald Cagle | 1 | 4 |
| Jake R. Nunn | 1 | 4 |
| Gaurav Aggarwal | 1 | 3 |
| Paul Wagner | 1 | 3 |
| Robert Hopfner | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.